Related Experiment Videos
Circulating CA 15.3 levels in breast cancer. Our present experience
R Colomer1, A Ruibal, M Navarro
1Section of Medical Oncology, Valle de Hebron General Hospital, Barcelona, Spain.
The International Journal of Biological Markers
|May 1, 1986
Summary
Serum CA 15.3 levels correlate with breast cancer stage and treatment response. Elevated CA 15.3 was observed in various malignancies, suggesting its utility as a breast cancer biomarker.
Area of Science:
- Oncology
- Biochemistry
Background:
- CA 15.3 is a tumor-associated antigen expressed by human breast carcinoma cells.
- Two monoclonal antibodies, 115D8 and DF3, define CA 15.3.
Purpose of the Study:
- To determine circulating serum levels of CA 15.3 in various patient groups.
- To assess the correlation of CA 15.3 levels with breast cancer stage and response to therapy.
Main Methods:
- Immunoradiometric assay (IRMA) was used to measure serum CA 15.3 levels.
- 1178 subjects including breast cancer patients, other malignancies, benign diseases, and healthy controls were analyzed.
- Statistical analysis was performed to compare CA 15.3 levels across different groups.
Main Results:
- A threshold of 40 U/ml was established using healthy controls and benign disease patients.
- Elevated CA 15.3 was found in 6.5% of patients with non-breast malignancies.
- In breast cancer patients, CA 15.3 levels significantly differed based on disease stage and response to therapy (p < 0.01).
- All patients with stage IV breast cancer and progressive disease had elevated CA 15.3 levels.
Conclusions:
- Circulating CA 15.3 antigen levels correlate with breast cancer stage.
- CA 15.3 levels reflect the response to breast cancer therapy.
- CA 15.3 shows potential as a biomarker in breast cancer management.